DRTS Alpha Tau Medical Ltd.; Tolmar Inc.
Price Chart
Executive Summary
Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercialization of Alpha DaRT in prostate cancer, with an option for bladder cancer. Tolmar will invest $20M at an $11.99/share premium (25% above 30-day VWAP), pay $15M for manufacturing capacity, and provide up to $161.5M in milestones. The deal validates Alpha Tau's platform and provides non-dilutive capital, but the stock is already up significantly on prior reports.
Key Financial Metrics
Actionable Insight
The deal provides near-term capital and long-term revenue potential, but the stock has already rallied ~25% on prior reports. Monitor for FDA trial progress and milestone triggers. The 60% net sales margin is highly favorable for Alpha Tau, but commercialization risk remains pre-approval.
Key Facts
- Tolmar gets exclusive U.S. commercialization rights for prostate cancer (20-year term from first sale) with option for bladder cancer.
- Tolmar makes $20M equity investment at $11.99/share (25% premium to 30-day VWAP) and $15M manufacturing facility investment.
- Up to $161.5M in clinical, regulatory, and commercial milestones for the first indication.
- Alpha Tau will manufacture Alpha DaRT and sell to Tolmar at 60% of net sales price (subject to adjustments).
- Tolmar holds right of first negotiation on new Alpha Tau products for U.S. urological cancers.
Financial Impact
Immediate $20M equity infusion at premium + $15M manufacturing investment; up to $161.5M in milestones; 60% net sales revenue share for Alpha Tau.
Risk Factors
- Alpha DaRT is still in clinical development; no guarantee of FDA approval.
- Milestone payments are contingent on achieving clinical/regulatory targets.
- Dilution from $20M equity investment at $11.99/share (though at premium).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
9d ago
|
Press Release
| $10.58 $10.29 | ▼ −2.74% | ▼ −3.14% | $9.85 (−6.90%) |
|
May 11, 2026
4w ago
|
Press Release
| $10.34 $9.88 | ▼ −4.45% | ▼ −4.31% | $9.85 (−4.74%) |
|
May 8, 2026
5w ago
|
Press Release
| $8.51 $10.34 | ▲ +21.50% | ▲ +21.27% | $9.85 (+15.75%) |
|
May 5, 2026
5w ago
|
Press Release
| $7.39 $7.59 | ▲ +2.71% | ▲ +1.32% | $9.85 (+33.29%) |
|
May 4, 2026
5w ago
|
Press Release
| $7.53 $7.39 | ▼ −1.86% | ▼ −2.65% | $9.85 (+30.81%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $7.91 $7.30 | ▼ −7.71% | ▼ −7.23% | $9.85 (+24.53%) |
|
Apr 23, 2026
7w ago
|
Press Release
| $7.98 $8.09 | ▲ +1.38% | ▲ +0.59% | $9.85 (+23.43%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $6.84 $7.04 | ▲ +2.92% | ▲ +3.03% | $9.85 (+44.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access